CLDN18 expression was downregulated in GC, lung cancer, and sarcoma (gastric stromal tumor) compared to their normal counterparts, whereas upregulation was found in esophageal, pancreatic, and prostate cancer. This evidence concerns the gene CLDN18 and sarcoma.